Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Nature Communications
|
September 7, 2023
Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β
Ulrich Hommel, Konstanze Hurth, Jean-Michel Rondeau, et al.
Journal of Medicinal Chemistry
|
June 17, 2017
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo
Edwige Lorthiois, Karen Anderson, Anna Vulpetti, et al.
Nature Chemical Biology
|
November 4, 2016
Small-molecule factor D inhibitors targeting the alternative complement pathway
Jürgen Maibaum, Sha-Mei Liao, Anna Vulpetti, et al.
ACS Medicinal Chemistry Letters
|
December 20, 2023
Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase
Klemens Hoegenauer, Shaojian An, Jake Axford, et al.
Journal of Medicinal Chemistry
|
April 18, 2019
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway
Rajeshri G Karki, James Powers, Nello Mainolfi, et al.
Journal of Medicinal Chemistry
|
June 11, 2004
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding
Paolo Pevarello, Maria Gabriella Brasca, Raffaella Amici, et al.
Journal of Medicinal Chemistry
|
May 10, 2024
Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches
Anna Vulpetti, Jean-Michel Rondeau, Marie-Hélène Bellance, et al.
Nature Communications
|
December 9, 2025
Fragment-based discovery enables direct targeting of the melanoma oncogene MITF
Deborah Castelletti, Jürgen Hinrichs, Goran Malojčić, et al.
Nature Communications
|
January 4, 2024
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Martin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Nature Communications
|
August 19, 2024
Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Martin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Nature Communications
|
September 7, 2023
Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β
Ulrich Hommel, Konstanze Hurth, Jean-Michel Rondeau, et al.
Journal of Medicinal Chemistry
|
June 17, 2017
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo
Edwige Lorthiois, Karen Anderson, Anna Vulpetti, et al.
Nature Chemical Biology
|
November 4, 2016
Small-molecule factor D inhibitors targeting the alternative complement pathway
Jürgen Maibaum, Sha-Mei Liao, Anna Vulpetti, et al.
ACS Medicinal Chemistry Letters
|
December 20, 2023
Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase
Klemens Hoegenauer, Shaojian An, Jake Axford, et al.
Journal of Medicinal Chemistry
|
April 18, 2019
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway
Rajeshri G Karki, James Powers, Nello Mainolfi, et al.
Journal of Medicinal Chemistry
|
June 11, 2004
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding
Paolo Pevarello, Maria Gabriella Brasca, Raffaella Amici, et al.
Journal of Medicinal Chemistry
|
May 10, 2024
Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches
Anna Vulpetti, Jean-Michel Rondeau, Marie-Hélène Bellance, et al.
Nature Communications
|
December 9, 2025
Fragment-based discovery enables direct targeting of the melanoma oncogene MITF
Deborah Castelletti, Jürgen Hinrichs, Goran Malojčić, et al.
Nature Communications
|
January 4, 2024
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Martin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Nature Communications
|
August 19, 2024
Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Martin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Page
of 6